

Rekonvaleszentenplasma bei viralen Erkrankungen – eine Zwischenbilanz

1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat.Microbiol.* 2020;5:36-544.
2. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020
3. Li Q, Guan X, Wu P et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N.Engl.J.Med.* 2020;10.
4. Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514-523.
5. Bai Y, Yao L, Wei T et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA* 2020
6. Hu Z, Song C, Xu C et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci.China Life Sci.* 2020
7. Rothe C, Schunk M, Sothmann P et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N.Engl.J.Med.* 2020;382:970-971.
8. Wei WE, Li Z, Chiew CJ et al. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb. Mortal.Wkly.Rep.* 2020;69:411-415.
9. Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann.Intern.Med.* 2020;172:577-582.
10. Guan WJ, Ni ZY, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N.Engl.J.Med.* 2020
11. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro.Surveill* 2020;25:
12. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020;395:689-697.
13. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro.Surveill* 2020;25:
14. Richardson S, Hirsch JS, Narasimhan M et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020
15. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020
16. Wu C, Chen X, Cai Y et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern.Med.* 2020
17. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020
18. Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. *Med.J.Aust.* 2020;10.
19. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N.Engl.J.Med.* 2020;NEJMoa2007764.
20. Grein J, Ohmagari N, Shin D et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N.Engl.J.Med.* 2020;382:2327-2336.
21. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet.* 2020;395:1569-1578.
22. Horby P, Lim WS, Emberson J et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv* 2020;2020.
23. Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. *BMJ.* 2020;370:m2648. doi: 10.1136/bmj.m2648.:m2648.

24. Spyropoulos AC, Levy JH, Ageno W et al. Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. *J.Thromb.Haemost.* 2020;10.
25. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020;135:2033-2040.
26. Tian X, Li C, Huang A et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg.Microbes.Infect.* 2020;9:382-385.
27. O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed. *JAMA* 2020;06.07.2020:online publication ahead of print.
28. Lurie N, Sharfstein JM, Goodman JL. The Development of COVID-19 Vaccines: Safeguards Needed. *JAMA* 2020
29. Zhu FC, Guan XH, Li YH et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. LID - S0140-6736(20)31605-6 [pii] LID - 10.1016/S0140-6736(20)31605-6 [doi].
30. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. *Clin.Microbiol.Infect.* 2004;10:1062-1066.
31. Huang LR, Chiu CM, Yeh SH et al. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. *J.Med.Virol.* 2004;73:338-346.
32. Woo PC, Lau SK, Wong BH et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. *Clin.Diagn.Lab Immunol.* 2004;11:665-668.
33. Chen W, Xu Z, Mu J et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. *J.Med.Microbiol.* 2004;53:435-438.
34. Chen X, Zhou B, Li M et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. *J.Infect.Dis.* 2004;189:1158-1163.
35. Mo H, Zeng G, Ren X et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology.* 2006;11:49-53.
36. Shi Y, Wan Z, Li L et al. Antibody responses against SARS-coronavirus and its nucleocapsid in SARS patients. *J.Clin.Virol.* 2004;31:66-68.
37. Qiu M, Shi Y, Guo Z et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. *Microbes.Infect.* 2005;7:882-889.
38. Lee N, Chan PK, Ip M et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. *J.Clin.Virol.* 2006;35:179-184.
39. Zhao J, Wang W, Wang W et al. Comparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARS. *Clin.Vaccine Immunol.* 2007;14:839-846.
40. Yang Z, Wang S, Li Q et al. Determining SARS sub-clinical infection: a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital. *Scand.J.Infect.Dis.* 2009;41:507-510.
41. Li G, Fan Y, Lai Y et al. Coronavirus infections and immune responses. *J.Med.Virol.* 2020;92:424-432.
42. Park WB, Perera RA, Choe PG et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. *Emerg. Infect.Dis.* 2015;21:2186-2189.
43. Choe PG, Perera RAPM, Park WB et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. *Emerg.Infect. Dis.* 2017;23:1079-1084.
44. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized cases of coronavirus disease 2019. *Nature* 2020;581:465-469.
45. Guo L, Ren L, Yang S et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin.Infect.Dis.* 2020
46. Robbiani DF, Gaebler C, Muecksch F et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* 2020;doi: 10.1038/s41586-020-2456-9.:online ahead of print.
47. Liu W, Liu L, Kou G et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. *J.Clin.Microbiol.* 2020;58:

48. Jahrsdorfer, B., Kroschel, J., Ludwig, C., Corman, V., Körper, S., Rojewski, M., Lotfi, R., Weinstock, C., Drosten, C., Seifried, E., Stamminger, T., Groß, H. J., and Schrezenmeier, H. Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing . 2020. Ref Type: Unpublished Work
49. Seydoux E, Homad LJ, MacCamy AJ et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity*. 2020
50. Katzelnick LC, Gresh L, Halloran ME et al. Antibody-dependent enhancement of severe dengue disease in humans. *Science* 2017;358:929-932.
51. Wan Y, Shang J, Sun S et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. *J.Virol.* 2020;94:
52. Dzik S. COVID-19 Convalescent Plasma: Now Is the Time for Better Science. *Transfus Med.Rev.* 2020
53. Liu L, Wei Q, Lin Q et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI.Insight.* 2019;4:
54. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J.Infect.Dis.* 2015;211:80-90.
55. Zhou XZ, Zhao M, Wang FS et al. [Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area]. *Zhonghua Yi.Xue.Za Zhi.* 2003;83:1018-1022.
56. Soo YO, Cheng Y, Wong R et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin.Microbiol.Infect.* 2004;10:676-678.
57. Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur.J.Clin.Microbiol.Infect.Dis.* 2005;24:44-46.
58. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. *J.Antimicrob.Chemother.* 2008;62:437-441.
59. Nie QH, Luo XD, Hui WL. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. *World J.Gastroenterol.* 2003;9:1139-1143.
60. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong.Kong.Med.J.* 2003;9:199-201.
61. Yeh KM, Chiueh TS, Siu LK et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J.Antimicrob.Chemother.* 2005;56:919-922.
62. Lai ST. Treatment of severe acute respiratory syndrome. *Eur.J.Clin.Microbiol.Infect.Dis.* 2005;24:583-591.
63. Arabi YM, Hajeer AH, Luke T et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. *Emerg. Infect.Dis.* 2016;22:1554-1561.
64. Sun M, Xu Y, He H et al. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy. *Int.J.Infect.Dis.* 2020
65. Shen C, Wang Z, Zhao F et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* 2020;323:1582-1589.
66. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc.Natl.Acad.Sci U.S.A* 2020;117:9490-9496.
67. Zeng QL, Yu ZJ, Gou JJ et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. *J.Infect.Dis.* 2020;222:38-43.
68. Zhang B, Liu S, Tan T et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Chest* 2020;158:e9-e13.
69. Xia X, Li K, Wu L et al. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion. *Blood* 2020
70. Hartman W, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest. *medRxiv* 2020

71. Erkurt MA, Sarici A, Berber A et al. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. *Transfus Apher Sci.* 2020;102867.
72. Perotti C, Baldanti F, Bruno R et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. *medRxiv* 20202020.
73. Perotti C, Del Fante C, Baldanti F et al. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. *Internal and Emergency Medicine* 2020
74. Salazar E, Perez KK, Ashraf M et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. *The American Journal of Pathology* 2020;190:1680-1690.
75. Jin C, Gu J, Yuan Y et al. Treatment of Six COVID-19 Patients with Convalescent Plasma. *medRxiv* 20202020.
76. Ye M, Fu D, Ren Y et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol* 2020;n/a:
77. Clark E, Guilpain P, Filip IL et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. *Br.J.Haematol.* 2020
78. Mira E, Yarce OA, Ortega C et al. Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *J.Allergy Clin.Immunol.Pract.* 2020
79. Ahn JY, Sohn Y, Lee SH et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. *J.Korean Med.Sci* 2020;35:e149.
80. Abdullah HM, Hama-Ali HH, Ahmed SN et al. A severe refractory COVID-19 patient responding to convalescent plasma; A case series. *Ann.Med.Surg.(Lond)* 2020;56:125-127.
81. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. *Case.Rep.Womens Health.* 2020;27:e00221. doi: 10.1016/j.crwh.2020.e00221.:e00221.
82. Kong Y, Cai C, Ling L et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. *Transfus Apher Sci.* 2020;102820.
83. Çinar OE, Sayinalp B, Aladağ KE et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. *Transfus Apher Sci.* 2020;102821.
84. Bao Y, Lin SY, Cheng ZH et al. Clinical Features of COVID-19 in a Young Man with Massive Cerebral Hemorrhage - Case Report. *SN Comprehensive Clinical Medicine* 2020;2:703-709.
85. Pei S, Yuan X, Zhimin Zhang Z et al. Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences. *medRxiv* 20202020.
86. Tan L, Kang X, Zhang B et al. A special case of COVID-19 with long duration of viral shedding for 49 days. *medRxiv* 20202020.
87. Joyner MJ, Wright RS, Fairweather D et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. *J.Clin.Invest* 2020
88. Liu STH, Lin HM, Baine I et al. Convalescent plasma treatment of severe COVID-19: A matched control study. *medRxiv* 20202020.
89. Abolghasemi H, Eshghi P, Cheraghali AM et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. *Transfus Apher Sci* 2020;102875.
90. Li L, Zhang W, Hu Y et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* 2020
91. Piechotta V, Chai KL, Valk SJ et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane.Database.Syst.Rev.* 2020;7:CD013600.
92. Kong, L. K. Letter to the Editor. *Transfus Apher Sci* 29, 101. 2003.)
93. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong.Kong.Med.J.* 2003;9:199-201.
94. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. *Hong.Kong.Med.J.* 2006;12:489.
95. Yu H, Gao Z, Feng Z et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. *PLoS.ONE.* 2008;3:e2985.

96. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. 1. N.Engl.J.Med. 2007;357:1450-1451.
97. Chan KK, Lee KL, Lam PK et al. Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). Hong.Kong.Med.J. 2010;16:447-454.
98. Duan, K., Liu, B., Li, C., Zhang, H., and Yu, T. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. 2020.
99. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin.Infect.Dis. 2011;52:447-456.
100. Körper S, Jahrsdörfer B, Appl T et al. Rekonvaleszentenplasma zur Behandlung von schwerem Covid-19: Rationale und Design einer randomisierten, offenen klinischen Studie von Rekonvaleszentenplasma verglichen mit bestmöglicher supportiver Behandlung (CAPSID-Studie). Transfusionsmedizin 2020; 10: 143-149.